Abstract
To evaluate the effect of first-line and subsequent therapies, the outcome of 1,558 patients with chronic lymphocytic leukemia from five prospective phase II/III trials conducted between 1999 and 2010 was analyzed. The 3-year overall survival rate was higher after first-line treatment with chemoimmunotherapies such as fludarabine/cyclophosphamide/rituximab (87.9%) or bendamustine/rituximab (90.7%) compared to chemotherapies without an antibody (fludarabine/cyclophosphamide: 84.6%; fludarabine: 77.5%; chlorambucil: 77.4%). Furthermore, the median overall survival was longer in patients receiving at least one antibody-containing regimen in any treatment line (94.4 months) compared to the survival in patients who never received an antibody (84.3 months, P<0.0001). Univariate Cox regression analysis demonstrated that patients who did receive antibody treatment had a 1.42-fold higher risk of death (hazard ratio, 1.42; 95% confidence interval: 1.185-1.694). Therapies administered at relapse were very heterogeneous. Only 55 of 368 patients (14.9%) who started second-line treatment >24 months after first-line therapy repeated the first-line regimen. Among 315 patients requiring treatment ≤24 months after first-line therapy, cyclophosph...Continue Reading
Citations
Nov 4, 2016·Leukemia & Lymphoma·Davide RossiGeorg Stüssi
Nov 24, 2016·Expert Opinion on Drug Safety·Anna Korycka-WołowiecTadeusz Robak
Nov 30, 2016·Leukemia & Lymphoma·Anna AsklidLotta Hansson
Feb 6, 2017·Leukemia Research·Steven J HuangCynthia L Toze
Apr 5, 2018·Leukemia & Lymphoma·Lina van der StratenMark-David Levin
Jun 28, 2018·European Journal of Haematology·Erel JoffeUNKNOWN Israeli CLL Study Group
Sep 7, 2018·Leukemia & Lymphoma·Ewelina ZiolkowskaAnna Korycka-Wolowiec
Oct 27, 2018·Pathology Oncology Research : POR·Róbert SzászTamás Schneider
May 10, 2019·Journal of Personalized Medicine·Maria KolesnikovaMarina Zenkova
Nov 5, 2019·Leukemia & Lymphoma·Rudolf WeideJochen Heymanns
Mar 7, 2018·Oncotarget·Ida K MyhrvoldSigrid S Skånland
Mar 9, 2017·Leukemia & Lymphoma·Driss ChaouiAlain Delmer
Dec 29, 2016·Journal of Oncology Practice·Lucio GordanBarry Fortner
Mar 21, 2020·Annals of Hematology·Lina van der StratenMark-David Levin
Jan 16, 2021·OncoTargets and Therapy·Xiangxin LiHao Li
Jul 19, 2021·Clinical Lymphoma, Myeloma & Leukemia·Neda AlrawashdhIvo Abraham